-
1 × ₨ 517.00
-
1 × ₨ 820.77
-
1 × ₨ 45.00
-
1 × ₨ 10.00
-
1 × ₨ 629.18
-
1 × ₨ 30.00
-
1 × ₨ 37.00
-
1 × ₨ 1,200.80
-
1 × ₨ 83.33
-
1 × ₨ 135.00
-
1 × ₨ 1,985.00
-
1 × ₨ 94.02
-
1 × ₨ 70.68
-
1 × ₨ 51.34
-
1 × ₨ 462.00
-
1 × ₨ 202.36
-
1 × ₨ 68.00
-
1 × ₨ 878.04
-
1 × ₨ 384.00
-
1 × ₨ 45.00
-
2 × ₨ 310.00
-
1 × ₨ 350.00
-
1 × ₨ 716.00
-
1 × ₨ 430.00
-
1 × ₨ 371.00
-
1 × ₨ 392.09
-
1 × ₨ 823.09
-
1 × ₨ 1,172.94
-
1 × ₨ 334.80
-
1 × ₨ 1,038.00
-
1 × ₨ 600.00
-
1 × ₨ 130.00
Roll over image to zoom in
SITAPIN 50MG
₨ 277.00₨ 308.00 (-10%)
- For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
- Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.
Reviews
There are no reviews yet.